bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S5 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

The characteristics of HBV-positive HCC patients in the prognostic analysis
Supplementary Figure 5 from Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer
Authors: Salem Ahmed , Little Ross A. , Latif Ayşe , Featherstone Adam K. , Babur Muhammad , Peset Isabel , Cheung Susan , Watson Yvonne , Tessyman Victoria , Mistry Hitesh , Ashton Garry , Behan Caron , Matthews Julian C. , Asselin Marie-Claude , Bristow Robert G. , Jackson Alan , Parker Geoff J.M. , Faivre-Finn Corinne , Williams Kaye J. , O'Connor James P.B.
Published: April 2023

Supplementary Figure 5
Supplementary Figure 3 from Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer
Authors: Salem Ahmed , Little Ross A. , Latif Ayşe , Featherstone Adam K. , Babur Muhammad , Peset Isabel , Cheung Susan , Watson Yvonne , Tessyman Victoria , Mistry Hitesh , Ashton Garry , Behan Caron , Matthews Julian C. , Asselin Marie-Claude , Bristow Robert G. , Jackson Alan , Parker Geoff J.M. , Faivre-Finn Corinne , Williams Kaye J. , O'Connor James P.B.
Published: April 2023

Supplementary Figure 3
Table S11 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

APOBEC3s and UNG mRNA expression levels in HCC tissues and adjusted liver tissues
Table S1 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

Locations of APOBEC-signature HBV mutations in the preS and the enhancer II/basal core promoter/precure regions
Supplementary Data from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

Supplementary methods and figure legends for supplementary figures
Supplementary Figure 1 from Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer
Authors: He Xuexin , Ji Jiali , Tian Mei , Esteva Francisco J. , Hortobagyi Gabriel N. , Yeung Sai-Ching Jim
Published: April 2023

Supplementary Figure S1. Restricted mean survival time among patients who received no adjuvant chemotherapy (group A) and patients who received adjuvant chemotherapy only (group B), in patients with pT1N0M0 HER2-positive breast cancer.
Supplementary Tables 1-3 from A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Authors: Harding James J. , Zhu Andrew X. , Bauer Todd M. , Choueiri Toni K. , Drilon Alexander , Voss Martin H. , Fuchs Charles S. , Abou-Alfa Ghassan K. , Wijayawardana Sameera R. , Wang Xuejing Aimee , Moser Brian A. , Uruñuela Arantxa , Wacheck Volker , Bendell Johanna C.
Published: April 2023

Supplementary Tables 1-3
Supplementary Figure Legends from A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Authors: Harding James J. , Zhu Andrew X. , Bauer Todd M. , Choueiri Toni K. , Drilon Alexander , Voss Martin H. , Fuchs Charles S. , Abou-Alfa Ghassan K. , Wijayawardana Sameera R. , Wang Xuejing Aimee , Moser Brian A. , Uruñuela Arantxa , Wacheck Volker , Bendell Johanna C.
Published: April 2023

Supplementary figures titles and legends are placed in this document
Supplementary Data from NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival
Authors: Muntasell Aura , Rojo Federico , Servitja Sonia , Rubio-Perez Carlota , Cabo Mariona , Tamborero David , Costa-García Marcel , Martínez-Garcia María , Menéndez Sílvia , Vazquez Ivonne , Lluch Ana , Gonzalez-Perez Abel , Rovira Ana , López-Botet Miguel , Albanell Joan
Published: April 2023

Supplementary Figure 1: HER2-positive Breast Cancer Study cohorts Supplementary Figure 2: TI-NK cells as categorical variable predicted pCR to anti-HER2 mAb-based neoadjuvant treatment with high sensitivity and specificity Supplementary Table I: TIL and TI-NK cell distribution according to tumor characteristics Supplementary Figure 3: Baseline TI-NK cell numbers association with DMFS in HER2-positive breast cancer patients receiving anti-HER2 mAb-based neoadjuvant therapy Supplementary Table II: Tumor HLA-I levels in relation to clinicopathological factors. Supplementary Figure 4: TI-NK cells associate with pCR regardless of tumor HLA-I expression levels. Supplementary Figure 5: Comparable clinical behavior of HLA low and HLA normal expressing tumors upon stratification by TI-NK cells.
Supplementary Figure 3C from A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Authors: Harding James J. , Zhu Andrew X. , Bauer Todd M. , Choueiri Toni K. , Drilon Alexander , Voss Martin H. , Fuchs Charles S. , Abou-Alfa Ghassan K. , Wijayawardana Sameera R. , Wang Xuejing Aimee , Moser Brian A. , Uruñuela Arantxa , Wacheck Volker , Bendell Johanna C.
Published: April 2023

Exploratory Analysis of Different MET Expression Cut-offs in HCC Cohort
Supplementary Figure 3B from A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Authors: Harding James J. , Zhu Andrew X. , Bauer Todd M. , Choueiri Toni K. , Drilon Alexander , Voss Martin H. , Fuchs Charles S. , Abou-Alfa Ghassan K. , Wijayawardana Sameera R. , Wang Xuejing Aimee , Moser Brian A. , Uruñuela Arantxa , Wacheck Volker , Bendell Johanna C.
Published: April 2023

Exploratory Analysis of Different MET Expression Cut-offs in HCC Cohort
Supplementary Figure 2D from A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Authors: Harding James J. , Zhu Andrew X. , Bauer Todd M. , Choueiri Toni K. , Drilon Alexander , Voss Martin H. , Fuchs Charles S. , Abou-Alfa Ghassan K. , Wijayawardana Sameera R. , Wang Xuejing Aimee , Moser Brian A. , Uruñuela Arantxa , Wacheck Volker , Bendell Johanna C.
Published: April 2023

Progression-free Survival in NSCLC population, MET +23
Supplementary Figure 2C from A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Authors: Harding James J. , Zhu Andrew X. , Bauer Todd M. , Choueiri Toni K. , Drilon Alexander , Voss Martin H. , Fuchs Charles S. , Abou-Alfa Ghassan K. , Wijayawardana Sameera R. , Wang Xuejing Aimee , Moser Brian A. , Uruñuela Arantxa , Wacheck Volker , Bendell Johanna C.
Published: April 2023

Progression-free Survival in RCC population, MET +23
Supplementary Video S6 from Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs
Authors: Kiseleva Anna A. , Korobeynikov Vladislav A. , Nikonova Anna S. , Zhang Peishan , Makhov Petr , Deneka Alexander Y. , Einarson Margret B. , Serebriiskii Ilya G. , Liu Hanqing , Peterson Jeffrey R. , Golemis Erica A.
Published: April 2023

Supplementary Video S6. Time-lapse images of hTERT-RPE1-Arl13b-GFP cells starved in serum-free Opti-MEM for 48 hours, then incubated for 3 hours in 2.5 µM IRAK1/4 inhibitor + 20% FBS.
Supplementary Figure 2A from A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Authors: Harding James J. , Zhu Andrew X. , Bauer Todd M. , Choueiri Toni K. , Drilon Alexander , Voss Martin H. , Fuchs Charles S. , Abou-Alfa Ghassan K. , Wijayawardana Sameera R. , Wang Xuejing Aimee , Moser Brian A. , Uruñuela Arantxa , Wacheck Volker , Bendell Johanna C.
Published: April 2023

Progression-free Survival in Gastric Cancer population, MET +23
Supplementary Figure 1 from A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Authors: Harding James J. , Zhu Andrew X. , Bauer Todd M. , Choueiri Toni K. , Drilon Alexander , Voss Martin H. , Fuchs Charles S. , Abou-Alfa Ghassan K. , Wijayawardana Sameera R. , Wang Xuejing Aimee , Moser Brian A. , Uruñuela Arantxa , Wacheck Volker , Bendell Johanna C.
Published: April 2023

Preclinical Data for Emibetuzumab and DC-101
Supplemental materials from Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
Authors: Li Qiao , Guan Xiuwen , Chen Shanshan , Yi Zongbi , Lan Bo , Xing Puyuan , Fan Ying , Wang Jiayu , Luo Yang , Yuan Peng , Cai Ruigang , Zhang Pin , Li Qing , Zhong Dafang , Zhang Yifan , Zou Jianjun , Zhu Xiaoyu , Ma Fei , Xu Binghe
Published: April 2023

Detailed protocols for ctDNA sequencing
Supplementary Video S1 from Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs
Authors: Kiseleva Anna A. , Korobeynikov Vladislav A. , Nikonova Anna S. , Zhang Peishan , Makhov Petr , Deneka Alexander Y. , Einarson Margret B. , Serebriiskii Ilya G. , Liu Hanqing , Peterson Jeffrey R. , Golemis Erica A.
Published: April 2023

Supplementary Video S1. Time-lapse images of hTERT-RPE1-Arl13b-GFP cells starved in serum-free Opti-MEM for 48 hours.
Supplementary Table S3 from Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs
Authors: Kiseleva Anna A. , Korobeynikov Vladislav A. , Nikonova Anna S. , Zhang Peishan , Makhov Petr , Deneka Alexander Y. , Einarson Margret B. , Serebriiskii Ilya G. , Liu Hanqing , Peterson Jeffrey R. , Golemis Erica A.
Published: April 2023

Supplementary Table S3. List of primers used for qRT-PCR.
Supplementary Table from PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Authors: Flaifel Abdallah , Xie Wanling , Braun David A. , Ficial Miriam , Bakouny Ziad , Nassar Amin H. , Jennings Rebecca B. , Escudier Bernard , George Daniel J. , Motzer Robert J. , Morris Michael J. , Powles Thomas , Wang Evelyn , Huang Ying , Freeman Gordon J. , Choueiri Toni K. , Signoretti Sabina
Published: April 2023

Supplementary Table 1. Patient demographic and clinical characteristics Supplementary Table 2. Associations of PD-L1 expression with response to therapy Supplementary Table 3. Treatment comparison on ORR and DCR, subgroup analysis by PD-L1 expression status on tumor cells (TC) Supplementary Table 4. Treatment comparison on PFS and OS, subgroup analysis by PD-L1 expression status on tumor cells (TC), immune cells (IC) or TC/IC combined scores*. Supplementary Table 5. Associations of MET and/or PD-L1 expression on tumor cells with treatment outcomes Supplementary Table 6. Treatment comparison on PFS and OS, subgroup analysis by MET and PD-L1 ({greater than or equal to}1% cutoff) expression on tumor cells Supplementary Table 7. Association of immune cell density (ICD) tertile groups* with PFS, OS, ORR and DCR Supplementary Table 8. Association of immune cell density (ICD) continuous scores with PFS and OS Supplementary Table 9. Treatment comparison on PFS and OS, subgroup analysis by immune cell density (ICD) (dichotomized at the upper 33% tertile value from the joint distribution of two trials)
Supplementary Figures and Tables from Rare, Pathogenic Germline Variants in Fanconi Anemia Genes Increase Risk for Squamous Lung Cancer
Authors: Esai Selvan Myvizhi , Klein Robert J. , Gümüş Zeynep H.
Published: April 2023

Supplementary Figures and Tables
Supplementary Figure 1 from PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Authors: Flaifel Abdallah , Xie Wanling , Braun David A. , Ficial Miriam , Bakouny Ziad , Nassar Amin H. , Jennings Rebecca B. , Escudier Bernard , George Daniel J. , Motzer Robert J. , Morris Michael J. , Powles Thomas , Wang Evelyn , Huang Ying , Freeman Gordon J. , Choueiri Toni K. , Signoretti Sabina
Published: April 2023

Figure S1 shows PD-L1 positive and negative staining
Supplementary Data from The Caspase-3/PKCδ/Akt/VEGF-A Signaling Pathway Mediates Tumor Repopulation during Radiotherapy
Authors: Cheng Jin , He Sijia , Wang Min , Zhou Ling , Zhang Zhengxiang , Feng Xiao , Yu Yang , Ma Jingjing , Dai Chenyun , Zhang Shengping , Sun Lianhui , Gong Yanping , Wang Yiwei , Zhao Minghui , Luo Yuntao , Liu Xinjian , Tian Ling , Li Chuanyuan , Huang Qian
Published: April 2023

Supplementary Data including Supplementary Figure Legends, Supplementary Figure S1-5 and Supplementary Table S1
Supplementary Data from TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer
Authors: Fucikova Jitka , Rakova Jana , Hensler Michal , Kasikova Lenka , Belicova Lucie , Hladikova Kamila , Truxova Iva , Skapa Petr , Laco Jan , Pecen Ladislav , Praznovec Ivan , Halaska Michael J. , Brtnicky Tomas , Kodet Roman , Fialova Anna , Pineau Josephine , Gey Alain , Tartour Eric , Ryska Ales , Galluzzi Lorenzo , Spisek Radek
Published: April 2023

Supplemental material, figures and tables Supplemental Figure 1. Experimental design of the study. Supplemental Figure 2. Tumor infiltration by CD8+ T cells, CD20+ B cells and DC-LAMP+ cells correlate with prolonged survival in patients with HGSC. Supplemental Figure 3. Representative images of PD-L1 (scale bar = 100 μm) and PD-1 (Scale bar = 50 μm ) immunostaining. Supplemental Figure 4. Representative images of CTLA4 (scale bar = 50 μm) and LAG-3 (Scale bar = 50 μm ) immunostaining. Supplemental Figure 5. PD-L1 levels and infiltration by PD-1+, CTLA4+ and LAG-3+ cells were heterogeneous across samples but did not differ based on site of assessment. Supplemental Figure 6. PD-L1, PD-1 and CTLA4 expression on freshly isolated CD8+ T cells after exposure to recombinant IFNγ. Supplemental Figure 7. Representative images of 3 different samples of PD-1Lo/CD8Lo, PD-1Hi/CD8Hi, PD-1Lo/CD20/DC-LAMPLo and PD-1Hi/CD20/DC-LAMPHi immunostaining. Scale bar = 100 μm. Supplemental Figure 8: The combined prognostic impact of CD8+ T cells and PD-1+, LAG-3+ and CTLA4+ cells in HGSC. Supplemental table 1. Main clinical and biological characteristics of 20 HGSC patients in which the freshly resected tumors were analyzed using flow cytometry (Study group 2). Supplemental Table 2. The list of antibodies used for IHC staining. Supplemental table 3. The list of antibodies used for flow cytometry. Supplemental Table 4. The list of genes used by MCP counter for identification of distinct cell populations. Supplemental Table 5. The list of antibodies used for in situ immunofluorescence staining. Supplemental Table 6. Genes differentially represented in PD-1Hi vs PD-1Lo HGSCs. Supplemental Table 7. Genes differentially represented in TIM-3Hi vs TIM-3Lo HGSCs. Supplemental Table 8. Results of biostatistic analysis comparing expression of PD-L1 and density of PD-1+, LAG-3+, CTLA4+, CD8+, DC-LAMP+ and CD20+ cells in tumor microenvironment of ImmuneHi/TIM-3Hi vs ImmuneHi/TIM-3Lo and ImmuneLo/TIM-3Hi vs ImmuneLo/TIM-3Lo.
Supplementary Data from The Caspase-3/PKCδ/Akt/VEGF-A Signaling Pathway Mediates Tumor Repopulation during Radiotherapy
Authors: Cheng Jin , He Sijia , Wang Min , Zhou Ling , Zhang Zhengxiang , Feng Xiao , Yu Yang , Ma Jingjing , Dai Chenyun , Zhang Shengping , Sun Lianhui , Gong Yanping , Wang Yiwei , Zhao Minghui , Luo Yuntao , Liu Xinjian , Tian Ling , Li Chuanyuan , Huang Qian
Published: April 2023

Supplementary Figures and Tables. // Figure S1, Survival fractions. Figure S2, Linearity of bioluminescence signals vs. Fluc-GFP-labeled tumor cell numbers. Figure S3, Cisplatin-induced dying tumor cells stimulated living tumor cell growth. Figure S4, DN_PKCÎ' (K378A) stably transduced HT-29 cells showed less growth stimulation effect when compared with wild-type HT-29 cells. Figure S5, A specific HIF1Î± inhibitor PX-478 2HCl remarkably suppressed the reporter cell growth on irradiated feeder cells. // Table S1, Summary of clinical characteristics in 68 patients of colorectal cancer.
Supplemental legend from Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma
Authors: Haas Naomi B. , Appleman Leonard J. , Stein Mark , Redlinger Maryann , Wilks Melissa , Xu Xiaowei , Onorati Angelique , Kalavacharla Anusha , Kim Taehyong , Zhen Chao Jie , Kadri Sabah , Segal Jeremy P. , Gimotty Phyllis A. , Davis Lisa E. , Amaravadi Ravi K.
Published: April 2023

Supplemental legend
Figure S4 - Expression of AR-FL and AR variants in LuCaP xenografts from Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer
Authors: Bernemann Christof , Humberg Verena , Thielen Barbara , Steinestel Julie , Chen Xin , Duensing Stefan , Schrader Andres J. , Boegemann Martin
Published: April 2023

A) Expression of AR-FL in LuCaP xenografts displaying significantly lower expression of AR-FL in LuCaP xenograft 136s2. B/C/D) Expression of AR splice variants AR-V3 (C), AR-V7 (D) and AR-V9. Abbreviations: NTC, non-template control
Figure S3 - Analysis of deletion or inversion events in clinical samples from Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer
Authors: Bernemann Christof , Humberg Verena , Thielen Barbara , Steinestel Julie , Chen Xin , Duensing Stefan , Schrader Andres J. , Boegemann Martin
Published: April 2023

A) Detection of a deletion event in LuCaP 86.2. This samples also displays signals of wildtype genomic DNA, displaying an AR-V567es positive sub-clone. B) Detection of an inversion event in LuCaP 136s2. Abbreviations: BPH, benign prostate hyperplasia
Figure S2 - Non-specific binding of AR-V567es detection PCR assays from Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer
Authors: Bernemann Christof , Humberg Verena , Thielen Barbara , Steinestel Julie , Chen Xin , Duensing Stefan , Schrader Andres J. , Boegemann Martin
Published: April 2023

Bioanalyzer images of PCR products of 7 different AR-V567es detection approaches in 6 samples (positive controls: 86.2 and 136s2; negative control: 136p8; patient samples: VL4KJ2 (AR-V567es positive) and 9V9DIB (AR-V567es negative); pSG5-plasmid DNA; NTC). bp numbers indicate PCR product size of either AR-V567es (lower number) or AR-FL (higher number). Red arrows in E and G indicate faint band of a PCR product related to AR-V567es expression in patient sample VL4KJ2; PCR assays #5 and #7. Abbreviations: NTC, non-template control; bp, base pairs
Supplementary Data from Bioactivation of Napabucasin Triggers Reactive Oxygen Species–Mediated Cancer Cell Death
Authors: Froeling Fieke E.M. , Swamynathan Manojit Mosur , Deschênes Astrid , Chio Iok In Christine , Brosnan Erin , Yao Melissa A. , Alagesan Priya , Lucito Matthew , Li Juying , Chang An-Yun , Trotman Lloyd C. , Belleau Pascal , Park Youngkyu , Rogoff Harry A. , Watson James D. , Tuveson David A.
Published: April 2023

Supplementary Figure Legends
Supplementary Legend from Mechanisms and Antitumor Activity of a Binary EGFR/DNA–Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide
Authors: Sharifi Zeinab , Abdulkarim Bassam , Meehan Brian , Rak Janusz , Daniel Paul , Schmitt Julie , Lauzon Nidia , Eppert Kolja , Duncan Heather M. , Petrecca Kevin , Guiot Marie-Christine , Jean-Claude Bertrand , Sabri Siham
Published: April 2023

Supplementary Legend
Supplementary Data from Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma
Authors: Qin Yi , Wu Chung W. , Taylor William R. , Sawas Tarek , Burger Kelli N. , Mahoney Douglas W. , Sun Zhifu , Yab Tracy C. , Lidgard Graham P. , Allawi Hatim T. , Buttar Navtej S. , Smyrk Thomas C. , Iyer Prasad G. , Katzka David A. , Ahlquist David A. , Kisiel John B.
Published: April 2023

Supplemental Figure 1. Plots of individual methylated DNA marker level distributions with respect to control versus case, further divided by stage.
Supplementary Figure S2 from Mechanisms and Antitumor Activity of a Binary EGFR/DNA–Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide
Authors: Sharifi Zeinab , Abdulkarim Bassam , Meehan Brian , Rak Janusz , Daniel Paul , Schmitt Julie , Lauzon Nidia , Eppert Kolja , Duncan Heather M. , Petrecca Kevin , Guiot Marie-Christine , Jean-Claude Bertrand , Sabri Siham
Published: April 2023

Figure S2 shows additional data on colony formation (A, B) autophosphorylation (C) and comet assays (D) for U87/EGFR isogenic cell lines.
Supplemental Figures from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Authors: Chung Sejin , Vail Paris , Witkiewicz Agnieszka K. , Knudsen Erik S.
Published: April 2023

Supplemental Figures S1-S8
Supplementary Figure S1 from Mechanisms and Antitumor Activity of a Binary EGFR/DNA–Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide
Authors: Sharifi Zeinab , Abdulkarim Bassam , Meehan Brian , Rak Janusz , Daniel Paul , Schmitt Julie , Lauzon Nidia , Eppert Kolja , Duncan Heather M. , Petrecca Kevin , Guiot Marie-Christine , Jean-Claude Bertrand , Sabri Siham
Published: April 2023

Figure S1 shows molecular structure of ZR2002
Supplementary Figure 6 from Mechanisms and Antitumor Activity of a Binary EGFR/DNA–Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide
Authors: Sharifi Zeinab , Abdulkarim Bassam , Meehan Brian , Rak Janusz , Daniel Paul , Schmitt Julie , Lauzon Nidia , Eppert Kolja , Duncan Heather M. , Petrecca Kevin , Guiot Marie-Christine , Jean-Claude Bertrand , Sabri Siham
Published: April 2023

Figure S6 shows quantitative analysis of the proliferation marker Ki-67 by immunohistochemical staining of brain tumor tissue collected from mice with orthotopic 1123IC7R tumors.
Supplemental Figure Legends from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Authors: Chung Sejin , Vail Paris , Witkiewicz Agnieszka K. , Knudsen Erik S.
Published: April 2023

Supplemental Figure Legends
Supplemental Data 1 from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Authors: Chung Sejin , Vail Paris , Witkiewicz Agnieszka K. , Knudsen Erik S.
Published: April 2023

Full list of genes in correlation analysis for Figure 3. Includes correlation coefficients and z-score values.
Supplementary Figures from Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma
Authors: Dieters-Castator Dylan Z. , Rambau Peter F. , Kelemen Linda E. , Siegers Gabrielle M. , Lajoie Gilles A. , Postovit Lynne-Marie , Köbel Martin
Published: April 2023

Workflow, proteins identified, gene ontology, tumour purity, Pearson correlation, staining controls and tissue microarray scoring, Q Exactive Plus results, and HGSC molecular subtype comparison
Supplementary Data from PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors
Authors: Tateishi Kensuke , Nakamura Taishi , Juratli Tareq A. , Williams Erik A. , Matsushita Yuko , Miyake Shigeta , Nishi Mayuko , Miller Julie J. , Tummala Shilpa S. , Fink Alexandria L. , Lelic Nina , Koerner Mara V.A. , Miyake Yohei , Sasame Jo , Fujimoto Kenji , Tanaka Takahiro , Minamimoto Ryogo , Matsunaga Shigeo , Mukaihara Shigeo , Shuto Takashi , Taguchi Hiroki , Udaka Naoko , Murata Hidetoshi , Ryo Akihide , Yamanaka Shoji , Curry William T. , Dias-Santagata Dora , Yamamoto Tetsuya , Ichimura Koichi , Batchelor Tracy T. , Chi Andrew S. , Iafrate A. John , Wakimoto Hiroaki , Cahill Daniel P.
Published: April 2023

Supplementary Figure Legend
Supplementary Materials from A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Authors: Kahl Brad S. , Hamadani Mehdi , Radford John , Carlo-Stella Carmelo , Caimi Paolo , Reid Erin , Feingold Jay M. , Ardeshna Kirit M. , Solh Melhem , Heffner Leonard T. , Ungar David , He Shui , Boni Joseph , Havenith Karin , O'Connor Owen A.
Published: April 2023

Supplementary Materials
Figure S3 from Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas
Authors: Frapolli Roberta , Bello Ezia , Ponzo Marianna , Craparotta Ilaria , Mannarino Laura , Ballabio Sara , Marchini Sergio , Carrassa Laura , Ubezio Paolo , Porcu Luca , Brich Silvia , Sanfilippo Roberta , Casali Paolo Giovanni , Gronchi Alessandro , Pilotti Silvana , D'Incalci Maurizio
Published: April 2023

Heatmap of key genes in adipogenesis process.
Supplementary Figure 1 from A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Authors: Kahl Brad S. , Hamadani Mehdi , Radford John , Carlo-Stella Carmelo , Caimi Paolo , Reid Erin , Feingold Jay M. , Ardeshna Kirit M. , Solh Melhem , Heffner Leonard T. , Ungar David , He Shui , Boni Joseph , Havenith Karin , O'Connor Owen A.
Published: April 2023

Supplementary Figure 1
Figure S2 from Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas
Authors: Frapolli Roberta , Bello Ezia , Ponzo Marianna , Craparotta Ilaria , Mannarino Laura , Ballabio Sara , Marchini Sergio , Carrassa Laura , Ubezio Paolo , Porcu Luca , Brich Silvia , Sanfilippo Roberta , Casali Paolo Giovanni , Gronchi Alessandro , Pilotti Silvana , D'Incalci Maurizio
Published: April 2023

Immunohistochemistry with anti-CD-31 antibody
Figure S1 from Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas
Authors: Frapolli Roberta , Bello Ezia , Ponzo Marianna , Craparotta Ilaria , Mannarino Laura , Ballabio Sara , Marchini Sergio , Carrassa Laura , Ubezio Paolo , Porcu Luca , Brich Silvia , Sanfilippo Roberta , Casali Paolo Giovanni , Gronchi Alessandro , Pilotti Silvana , D'Incalci Maurizio
Published: April 2023

Antitumor activity of trabectedin, pioglitazone and their combination in ML004 PDX.
Supplementary Figure Legends from The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
Authors: Heisey Daniel A.R. , Lochmann Timothy L. , Floros Konstantinos V. , Coon Colin M. , Powell Krista M. , Jacob Sheeba , Calbert Marissa L. , Ghotra Maninderjit S. , Stein Giovanna T. , Maves Yuki Kato , Smith Steven C. , Benes Cyril H. , Leverson Joel D. , Souers Andrew J. , Boikos Sosipatros A. , Faber Anthony C.
Published: April 2023

Figure legends for Supplementary Figures S1-S8.
Figure S5 from The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
Authors: Heisey Daniel A.R. , Lochmann Timothy L. , Floros Konstantinos V. , Coon Colin M. , Powell Krista M. , Jacob Sheeba , Calbert Marissa L. , Ghotra Maninderjit S. , Stein Giovanna T. , Maves Yuki Kato , Smith Steven C. , Benes Cyril H. , Leverson Joel D. , Souers Andrew J. , Boikos Sosipatros A. , Faber Anthony C.
Published: April 2023

Navitoclax sensitizes EWFT to olaparib
Figure S1 from The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
Authors: Heisey Daniel A.R. , Lochmann Timothy L. , Floros Konstantinos V. , Coon Colin M. , Powell Krista M. , Jacob Sheeba , Calbert Marissa L. , Ghotra Maninderjit S. , Stein Giovanna T. , Maves Yuki Kato , Smith Steven C. , Benes Cyril H. , Leverson Joel D. , Souers Andrew J. , Boikos Sosipatros A. , Faber Anthony C.
Published: April 2023

Melting Curves
Table S1 from Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma
Authors: Peng Weiyi , Williams Leila J. , Xu Chunyu , Melendez Brenda , McKenzie Jodi A. , Chen Yuan , Jackson Heather L. , Voo Kui S. , Mbofung Rina M. , Leahey Sara Elizabeth , Wang Jian , Lizee Gregory , Tawbi Hussein A. , Davies Michael A. , Hoos Axel , Smothers James , Srinivasan Roopa , Paul Elaine M. , Yanamandra Niranjan , Hwu Patrick
Published: April 2023

List of detailed information for antibodies used for CytoF and Flow Cytometry
Figure S4 from Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma
Authors: Peng Weiyi , Williams Leila J. , Xu Chunyu , Melendez Brenda , McKenzie Jodi A. , Chen Yuan , Jackson Heather L. , Voo Kui S. , Mbofung Rina M. , Leahey Sara Elizabeth , Wang Jian , Lizee Gregory , Tawbi Hussein A. , Davies Michael A. , Hoos Axel , Smothers James , Srinivasan Roopa , Paul Elaine M. , Yanamandra Niranjan , Hwu Patrick
Published: April 2023

The cytokine changes in mice receiving PI3K inhibition in combination with anti-OX40 treatment.
Figure S6 from Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction
Authors: Carbajosa Sofía , Pansa María Florencia , Paviolo Natalia S. , Castellaro Andrés M. , Andino Diego L. , Nigra Ayelén D. , García Iris Alejandra , Racca Ana C. , Rodriguez-Berdini Lucía , Angiolini Virginia , Guantay Laura , Villafañez Florencia , Federico María Belén , Rodríguez-Baili María Celeste , Caputto Beatriz L. , Drewes Gerard , Madauss Kevin P. , Gloger Israel , Fernandez Elmer , Gil Germán A. , Bocco José Luis , Gottifredi Vanesa , Soria Gastón
Published: April 2023

Legends included in the figure file
Figure S2 from Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma
Authors: Peng Weiyi , Williams Leila J. , Xu Chunyu , Melendez Brenda , McKenzie Jodi A. , Chen Yuan , Jackson Heather L. , Voo Kui S. , Mbofung Rina M. , Leahey Sara Elizabeth , Wang Jian , Lizee Gregory , Tawbi Hussein A. , Davies Michael A. , Hoos Axel , Smothers James , Srinivasan Roopa , Paul Elaine M. , Yanamandra Niranjan , Hwu Patrick
Published: April 2023

Positively interaction of OX40 agonist antibody and PI3K inhibition in mice bearing PTEN-loss tumors
Figure S3 from Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction
Authors: Carbajosa Sofía , Pansa María Florencia , Paviolo Natalia S. , Castellaro Andrés M. , Andino Diego L. , Nigra Ayelén D. , García Iris Alejandra , Racca Ana C. , Rodriguez-Berdini Lucía , Angiolini Virginia , Guantay Laura , Villafañez Florencia , Federico María Belén , Rodríguez-Baili María Celeste , Caputto Beatriz L. , Drewes Gerard , Madauss Kevin P. , Gloger Israel , Fernandez Elmer , Gil Germán A. , Bocco José Luis , Gottifredi Vanesa , Soria Gastón
Published: April 2023

Legends included in the figure file
Figure S2 from Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction
Authors: Carbajosa Sofía , Pansa María Florencia , Paviolo Natalia S. , Castellaro Andrés M. , Andino Diego L. , Nigra Ayelén D. , García Iris Alejandra , Racca Ana C. , Rodriguez-Berdini Lucía , Angiolini Virginia , Guantay Laura , Villafañez Florencia , Federico María Belén , Rodríguez-Baili María Celeste , Caputto Beatriz L. , Drewes Gerard , Madauss Kevin P. , Gloger Israel , Fernandez Elmer , Gil Germán A. , Bocco José Luis , Gottifredi Vanesa , Soria Gastón
Published: April 2023

Legends included in the figure file
Figure S1 from Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction
Authors: Carbajosa Sofía , Pansa María Florencia , Paviolo Natalia S. , Castellaro Andrés M. , Andino Diego L. , Nigra Ayelén D. , García Iris Alejandra , Racca Ana C. , Rodriguez-Berdini Lucía , Angiolini Virginia , Guantay Laura , Villafañez Florencia , Federico María Belén , Rodríguez-Baili María Celeste , Caputto Beatriz L. , Drewes Gerard , Madauss Kevin P. , Gloger Israel , Fernandez Elmer , Gil Germán A. , Bocco José Luis , Gottifredi Vanesa , Soria Gastón
Published: April 2023

Legends included in the figure file
Supplementary figures from Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
Authors: Spratt Daniel E. , Alshalalfa Mohammed , Fishbane Nick , Weiner Adam B. , Mehra Rohit , Mahal Brandon A. , Lehrer Jonathan , Liu Yang , Zhao Shuang G. , Speers Corey , Morgan Todd M. , Dicker Adam P. , Freedland Stephen J. , Karnes R. Jeffery , Weinmann Sheila , Davicioni Elai , Ross Ashley E. , Den Robert B. , Nguyen Paul L. , Feng Felix Y. , Lotan Tamara L. , Chinnaiyan Arul M. , Schaeffer Edward M.
Published: April 2023

supp figures
Supplementary Method from A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Authors: Song Yuqin , Wu Jianqiu , Chen Xinchuan , Lin Tongyu , Cao Junning , Liu Yanyan , Zhao Yaozhong , Jin Jie , Huang Haiwen , Hu Jianda , Luo Jun , Zhang Liling , Xue Hongwei , Zhang Qingyuan , Wang Weiwei , Chen Chunxia , Feng Jifeng , Zhu Jun
Published: April 2023

Full inclusion and exclusion criteria
Supplementary Table S3 from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
Authors: Lazzari Luca , Corti Giorgio , Picco Gabriele , Isella Claudio , Montone Monica , Arcella Pamela , Durinikova Erika , Zanella Eugenia R. , Novara Luca , Barbosa Fabiane , Cassingena Andrea , Cancelliere Carlotta , Medico Enzo , Sartore-Bianchi Andrea , Siena Salvatore , Garnett Mathew J. , Bertotti Andrea , Trusolino Livio , Di Nicolantonio Federica , Linnebacher Michael , Bardelli Alberto , Arena Sabrina
Published: April 2023

Supplementary Table S3
Supplementary Methods from Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
Authors: Ponnusamy Suriyan , He Yali , Hwang Dong-Jin , Thiyagarajan Thirumagal , Houtman Rene , Bocharova Vera , Sumpter Bobby G. , Fernandez Elias , Johnson Daniel , Du Ziyun , Pfeffer Lawrence M. , Getzenberg Robert H. , McEwan Iain J. , Miller Duane D. , Narayanan Ramesh
Published: April 2023

Suppl. Methods
Supplementary Figures and Tables from Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
Authors: Ponnusamy Suriyan , He Yali , Hwang Dong-Jin , Thiyagarajan Thirumagal , Houtman Rene , Bocharova Vera , Sumpter Bobby G. , Fernandez Elias , Johnson Daniel , Du Ziyun , Pfeffer Lawrence M. , Getzenberg Robert H. , McEwan Iain J. , Miller Duane D. , Narayanan Ramesh
Published: April 2023

Supplementary Figures and Tables
Supplementary Data from Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors
Authors: Yap Timothy A. , Winter Jane N. , Giulino-Roth Lisa , Longley Jemma , Lopez Juanita , Michot Jean-Marie , Leonard John P. , Ribrag Vincent , McCabe Michael T. , Creasy Caretha L. , Stern Melissa , Pene Dumitrescu Teodora , Wang Xiaowei , Frey Steve , Carver Jennifer , Horner Thierry , Oh Choon , Khaled Ahmed , Dhar Arindam , Johnson Peter W.M.
Published: April 2023

Supplementary data
Supplementary Data from VEGFR1+ Metastasis–Associated Macrophages Contribute to Metastatic Angiogenesis and Influence Colorectal Cancer Patient Outcome
Authors: Freire Valls Aida , Knipper Karl , Giannakouri Evangelia , Sarachaga Víctor , Hinterkopf Sascha , Wuehrl Michael , Shen Ying , Radhakrishnan Praveenkumar , Klose Johannes , Ulrich Alexis , Schneider Martin , Augustin Hellmut G. , Ruiz de Almodovar Carmen , Schmidt Thomas
Published: April 2023

Figure S1. MAMs are more angiogenic and express more Flt1 than TAMs. Figure S2. Efficient depletion of Flt1 in CD11b+ cells. Figure S3. Macrophage infiltration, vessel density and VEGFR1+ cells have no impact on overall survival in patients with primary tumor and liver metastasis of colorectal cancer. Figure S4. Vessel density and VEGFR1 expression influence progression-free survival in patients with synchronous liver metastasis of colorectal cancer. Figure S5. No differences between pTU and LM in the total number of stained cells.
Supplementary Data from Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma
Authors: Nguyen Rosa , Moustaki Ardiana , Norrie Jacqueline L. , Brown Shantel , Akers Walter J. , Shirinifard Abbas , Dyer Michael A.
Published: April 2023

Supplementary Figure 5 A, Differential gene expression of IL-15-treated NK cells compared to IL-2. B, Functional categories of differentially expressed genes.
Figure S4 from Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma
Authors: Nguyen Rosa , Moustaki Ardiana , Norrie Jacqueline L. , Brown Shantel , Akers Walter J. , Shirinifard Abbas , Dyer Michael A.
Published: April 2023

Supplementary Figure S4 Weekly weight trends in mice treated with chemotherapy or chemoimmunotherapy.
Supplementary Figure 1 from Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer
Authors: Guillén Díaz-Maroto Natalia , Sanz-Pamplona Rebeca , Berdiel-Acer Mireia , Cimas Francisco J. , García Elena , Gonçalves-Ribeiro Samuel , Albert Nerea , Garcia-Vicién Gemma , Capella Gabriel , Moreno Victor , Salazar Ramon , Villanueva Alberto , Molleví David G.
Published: April 2023

Supplementary Figure 1
Supplementary Data from Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer
Authors: Guillén Díaz-Maroto Natalia , Sanz-Pamplona Rebeca , Berdiel-Acer Mireia , Cimas Francisco J. , García Elena , Gonçalves-Ribeiro Samuel , Albert Nerea , Garcia-Vicién Gemma , Capella Gabriel , Moreno Victor , Salazar Ramon , Villanueva Alberto , Molleví David G.
Published: April 2023

Supplementary methods and results. Supplementary figure legends
Figure S2 from Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma
Authors: Nguyen Rosa , Moustaki Ardiana , Norrie Jacqueline L. , Brown Shantel , Akers Walter J. , Shirinifard Abbas , Dyer Michael A.
Published: April 2023

Supplementary Figure S2. Cytotoxic activity of NK cells from CD1-Foxn1nu mice. A, The MHC class II-deficient mouse lymphoma cell line, YAC-1, was used to test NK cell cytotoxicity. B, IL-2 (dark gray) or IL-15-activated (light gray) NK cells isolated from the spleen of CD1-Foxn1nu mice were plated with YAC-1 cells at an E:T ratio of 5:1 and 2.5:1 for the duration of 4 hours. Specific tumor lysis was significantly higher with NK cells activated with IL-15 than with IL-2. C, Xenoreactivity of murine NK cells against K562 and SJNBL46_X (PDX) with (+AB) and without antibody compared to YAC-1. D, CD107a expression was increased in IL-2- and IL-15-preactivated NK cells compared to resting NK cells after co-culture with YAC-1. E, To quantitate IFN-Î³ expression, NK cells were stimulated with IL-12/IL-18 in culture (red). Unstimulated NK cells served as controls (gray). IL-15 preactivation was associated with higher IFN-Î³ expression than was IL-2 or no preactivation. F, Expression analysis of perforin and granzyme B. The expression of perforin was slightly higher in IL-15 than in IL-2-activated NK cells; however, granzyme B was similar.
Figure S1 from Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma
Authors: Nguyen Rosa , Moustaki Ardiana , Norrie Jacqueline L. , Brown Shantel , Akers Walter J. , Shirinifard Abbas , Dyer Michael A.
Published: April 2023

Supplementary Figure 1. Expression of NK cell exhaustion markers in tumorsphere-infiltrating and non-infiltrating NK cells by flow cytometry.
Supplementary Data from PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma
Authors: Smith Henry G. , Mansfield David , Roulstone Victoria , Kyula-Currie Joan N. , McLaughlin Martin , Patel Radhika R. , Bergerhoff Katharina F. , Paget James T. , Dillon Magnus T. , Khan Aadil , Melcher Alan , Thway Khin , Harrington Kevin J. , Hayes Andrew J.
Published: April 2023

Supplementary tables and figures
Supplementary Tables from A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection
Authors: Hess Julia , Unger Kristian , Maihoefer Cornelius , Schüttrumpf Lars , Wintergerst Ludmila , Heider Theresa , Weber Peter , Marschner Sebastian , Braselmann Herbert , Samaga Daniel , Kuger Sebastian , Pflugradt Ulrike , Baumeister Philipp , Walch Axel , Woischke Christine , Kirchner Thomas , Werner Martin , Werner Kristin , Baumann Michael , Budach Volker , Combs Stephanie E. , Debus Jürgen , Grosu Anca-Ligia , Krause Mechthild , Linge Annett , Rödel Claus , Stuschke Martin , Zips Daniel , Zitzelsberger Horst , Ganswindt Ute , Henke Michael , Belka Claus
Published: April 2023

Supplementary Tables 1-4
Supplementary Methods from A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection
Authors: Hess Julia , Unger Kristian , Maihoefer Cornelius , Schüttrumpf Lars , Wintergerst Ludmila , Heider Theresa , Weber Peter , Marschner Sebastian , Braselmann Herbert , Samaga Daniel , Kuger Sebastian , Pflugradt Ulrike , Baumeister Philipp , Walch Axel , Woischke Christine , Kirchner Thomas , Werner Martin , Werner Kristin , Baumann Michael , Budach Volker , Combs Stephanie E. , Debus Jürgen , Grosu Anca-Ligia , Krause Mechthild , Linge Annett , Rödel Claus , Stuschke Martin , Zips Daniel , Zitzelsberger Horst , Ganswindt Ute , Henke Michael , Belka Claus
Published: April 2023

Supplementary Methods
Supplementary Figure S5 from Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity
Authors: Current Kyle , Meyer Catherine , Magyar Clara E. , Mona Christine E. , Almajano Joel , Slavik Roger , Stuparu Andreea D. , Cheng Chloe , Dawson David W. , Radu Caius G. , Czernin Johannes , Lueckerath Katharina
Published: April 2023

Characterization of the PC-3 tumor model
Supplementary Legends from Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
Authors: Prabhu Varun V. , Madhukar Neel S. , Gilvary Coryandar , Kline C. Leah B. , Oster Sophie , El-Deiry Wafik S. , Elemento Olivier , Doherty Faye , VanEngelenburg Alexander , Durrant Jessica , Tarapore Rohinton S. , Deacon Sean , Charter Neil , Jung Jinkyu , Park Deric M. , Gilbert Mark R. , Rusert Jessica , Wechsler-Reya Robert , Arrillaga-Romany Isabel , Batchelor Tracy T. , Wen Patrick Y. , Oster Wolfgang , Allen Joshua E.
Published: April 2023

Supplementary legends for Figures S1-S5 and Tables S1-S2.
Figure S5 from Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
Authors: Prabhu Varun V. , Madhukar Neel S. , Gilvary Coryandar , Kline C. Leah B. , Oster Sophie , El-Deiry Wafik S. , Elemento Olivier , Doherty Faye , VanEngelenburg Alexander , Durrant Jessica , Tarapore Rohinton S. , Deacon Sean , Charter Neil , Jung Jinkyu , Park Deric M. , Gilbert Mark R. , Rusert Jessica , Wechsler-Reya Robert , Arrillaga-Romany Isabel , Batchelor Tracy T. , Wen Patrick Y. , Oster Wolfgang , Allen Joshua E.
Published: April 2023

Figure S5
Supplementary Figure S2 from Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity
Authors: Current Kyle , Meyer Catherine , Magyar Clara E. , Mona Christine E. , Almajano Joel , Slavik Roger , Stuparu Andreea D. , Cheng Chloe , Dawson David W. , Radu Caius G. , Czernin Johannes , Lueckerath Katharina
Published: April 2023

Absolute tumor volumes and bodyweights
Figure S2 from Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
Authors: Prabhu Varun V. , Madhukar Neel S. , Gilvary Coryandar , Kline C. Leah B. , Oster Sophie , El-Deiry Wafik S. , Elemento Olivier , Doherty Faye , VanEngelenburg Alexander , Durrant Jessica , Tarapore Rohinton S. , Deacon Sean , Charter Neil , Jung Jinkyu , Park Deric M. , Gilbert Mark R. , Rusert Jessica , Wechsler-Reya Robert , Arrillaga-Romany Isabel , Batchelor Tracy T. , Wen Patrick Y. , Oster Wolfgang , Allen Joshua E.
Published: April 2023

Figure S2
Supplementary Figure 5 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate
Authors: Lee Oukseub , Sullivan Megan E. , Xu Yanfei , Rogers Chiara , Muzzio Miguel , Helenowski Irene , Shidfar Ali , Zeng Zexian , Singhal Hari , Jovanovic Borko , Hansen Nora , Bethke Kevin P. , Gann Peter H. , Gradishar William , Kim J. Julie , Clare Susan E. , Khan Seema A.
Published: April 2023

Supplemental Figure 5. Ki67 Change was not associated with drug concentration in Tumor samples. Tumor samples were available for quantitation from 22 women.
Supplementary Figure 4 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate
Authors: Lee Oukseub , Sullivan Megan E. , Xu Yanfei , Rogers Chiara , Muzzio Miguel , Helenowski Irene , Shidfar Ali , Zeng Zexian , Singhal Hari , Jovanovic Borko , Hansen Nora , Bethke Kevin P. , Gann Peter H. , Gradishar William , Kim J. Julie , Clare Susan E. , Khan Seema A.
Published: April 2023

Supplemental Figure 4. Plots showing changes in serum estradiol (left panel) and serum progesterone (right panel) in three subgroups: placebo, TPA-treated Ki67 responders and TPA-treated Ki67-nonresponders.
Supplementary Figure 3 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate
Authors: Lee Oukseub , Sullivan Megan E. , Xu Yanfei , Rogers Chiara , Muzzio Miguel , Helenowski Irene , Shidfar Ali , Zeng Zexian , Singhal Hari , Jovanovic Borko , Hansen Nora , Bethke Kevin P. , Gann Peter H. , Gradishar William , Kim J. Julie , Clare Susan E. , Khan Seema A.
Published: April 2023

Supplemental Figure 3. Validation of RNA seq results of responders by Nanostring nCounter gene expression assay